A variant of c6 .beta.-chemokine leukotactin-1(shlkn-1) with enhanced biological activity
CA 2374409 A1 · Owner: Kwon, Byoung S. · Inventors: Baek, Seung Jae; Lee, Kong-Ju; Lee, Eun-Kyoung
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1 a process for , preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection the , protection of bone marrow stem cells during chemotherapy or radiotherapy and , the inhibition of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 27, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 27, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 27, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.